United Microelectronics Corporation (UMC): what the price requires

At today's price, United Microelectronics Corporation (UMC) is priced for No valuation family reaches the price: it is rich on assets, earnings power, peers, and.... boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high.

Generated: 2026-07-08 · Exported: 2026-07-11 · Source: https://boothcheck.com/report/UMC

Headline

FieldValue
TickerUMC
CompanyUnited Microelectronics Corporation
Sector / IndustryTechnology / Semiconductors
Current price$24.46/sh
CompositionWafer 96% / Others 4%

Valuation X-Ray

No valuation family reaches the price: it is rich on assets, earnings power, peers, and even forward growth. The price is a bet beyond what any standard frame supports.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

FamilyMedian price/FVModelsReads
Asset4.46x5expensive
Earnings3.77x3expensive
Relative1.50x5expensive
Growth1.29x2expensive

Families that call it expensive: Asset, Earnings, Relative

The models below discount at their own flat-beta convention rates (cost of equity 11.8%, WACC 11.2%); the inversion above states its own rate.

Per-Model Detail (n=15)

ModelFamilyFVPrice/FVApplicableMethodology
DCF Perpetual GrowthGrowth$0.9924.70xyesFCF base $0.2B, growth 9% (input: historical growth), terminal g 4.0%, WACC 11.2%, 6yr projection (excluded from median)
DCF Exit MultipleGrowth$18.891.29xyesExit EV/EBITDA: 36.1x / 38.1x / 40.1x (bear / base = today's held flat / bull), 6yr
Relative ValuationRelative$16.291.50xyesP/E 27.43x (blended: sector 22x + trailing (TTM) 40x), scenarios: 22.6x / 27.4x / 32.3x (bear / base = sector held flat / bull), EV/EBITDA 22.62x
Simple DDMGrowthno
Two-Stage DDMGrowthno
Simple Excess ReturnAsset$5.194.71xyesBV/sh $4.58, ROE (TTM) 13.3%, ke 11.8%
Two-Stage Excess ReturnAsset$5.484.46xyes5yr excess ROE then converge to ke=11.8%
Discounted Future Market CapGrowth$18.971.29xyesRev $7.1B, growth 9% (input: historical growth; tapered), Terminal P/S: 6.9x / 8.3x / 9.8x (bear / base = today's held flat / bull, cap 12x)
Peter Lynch Fair ValueRelative$17.391.41xyesEPS $0.60, growth 29% (input: historical EPS growth), PEG=1.38 (Fair)
Margin TrajectoryGrowthno
Earnings Power ValueEarnings$5.924.13xyesNormalized EBIT (5y avg op income, one-time charges added back) $1.90B × (1−15%) / WACC 11.2% → EPV (no growth)
Residual IncomeAsset$5.554.41xyesBV $4.58 + 5yr PV of (ROE (TTM) 13.3% − Kₑ 11.8%) × BV; BV grows 8.7%/yr
Graham NumberAsset$7.863.11xyes√(22.5 × EPS $0.60 × BVPS $4.58) — Graham's conservative floor
EV/EBITDA RelativeRelative$10.192.40xyesEBITDA $1.57B × sector EV/EBITDA 16.0x
FCF YieldEarnings$0.4258.23xyesFCF $162.5M / Kₑ 11.8% — zero-growth perpetuity (excluded from median)
SBC-Adj FCF YieldEarningsno
Ben Graham FormulaEarnings$19.361.26xyesEPS $0.60 × (8.5 + 2×15.0%) × (4.4 / 5.3%)
ROIC-Justified P/BAsset$4.795.11xyesBV $4.58 × (ROIC 11.7% / WACC 11.2%)
P/Sales SectorRelative$14.681.67xyesRevenue $7.15B × sector P/S 5.0x
PEG Fair ValueRelative$22.501.09xyesEPS $0.60 × (PEG 1.5 × growth 25.0% (input: historical EPS growth)) → PE 37.5x
Earnings YieldEarnings$6.493.77xyesEPS $0.60 / required return 9.3% (Rf 4.3% + ERP 5.0%)
Funds From Operations MultipleRelativeno
Clinical Phase NPVGrowthno
MertonAssetno
V5 Mechanicalno

Solvency

FieldValue
Net cash$3.2b
Net debt / NOPAT (after-tax)-0.43x (net cash)
Net debt / operating income (pre-tax)-0.37x (net cash)
Interest coverage36.9x
Burning cashno

Peer Cohorts (Per Segment, With Filing Citations)

Core business (reported)

Methodology Note

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.

View the full interactive UMC report on boothcheck